Biotech Values

[genisi]

MDCO believes that most companies will find it difficult to make bivalirudin in necessary ton quantity. Perhaps the facts that Hatch-Waxman exclusivity expired Nov 2008 and no paragraph IV filings have occurred, imply that generics might have a high manufacturing hurdle.